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Abstract
We hypothesized that the magnitude of the association between plasma homocysteine concentration and cognitive performance is larger for
ApoE-4 carriers than for non-carriers. Nine hundred eleven dementia-free and stroke-free subjects (59% women) from the Maine-Syracuse study
(26–98 years old) were stratified into no-ApoE-4 (n = 667) and ApoE-4 carrier (n = 244) cohorts. Employing a cross-sectional design and multiple
regression analyses, plasma homocysteine was related to multiple domains of cognitive performance within these cohorts. When unadjusted, and
with adjustment for age, education, gender, ethnicity, and previous cognitive examinations, homocysteine concentrations were inversely related
to cognitive performance within both ApoE cohorts, with higher magnitude of associations within the ApoE-4 cohort. With adjustment for
cardiovascular disease risk factors, cardiovascular disease, and B-vitamin concentrations, the higher magnitude of associations between plasma
homocysteine and cognitive performance within the ApoE-4 cohort relative to the no-ApoE-4 cohort persisted; but associations of plasma
homocysteine and cognitive performance were attenuated and no longer significant within the no-ApoE-4 cohort. Presence of the ApoE-4 allele
modifies the relation between plasma homocysteine and cognitive performance.
© 2007 Elsevier Ireland Ltd. All rights reserved.
Keywords: ApoE; Homocysteine; Cardiovascular risk factors; Vitamins; Cognitive performance
Elevated plasma homocysteine (tHcy) is a risk factor for
cognitive deficit [2,7,11,12,28,33,37,38,45], cognitive decline
[26,46], and dementia [5,25,40]. It has been hypothesized that
tHcy is associated with lowered cognitive function via its posi-
tive association with other risk factors for cardiovascular disease
(CVD) and CVD-related events [11,12,35]. Other possibilities
are that vitamins involved in tHcy metabolism, folic acid, vita-
min B6 and vitamin B12, [39] confound relations between tHcy
and cognition [19] and/or tHcy itself has neurotoxic and excito-
toxic properties [14,20,24,32].
ApoE is a lipoprotein involved in lipid transport and neu-
ronal repair and synaptogenesis after injury [30]. The protein has
three isoforms, ApoE-2, ApoE-3, and ApoE-4. The ApoE-4
genotype represents a genetic risk factor for Alzheimer’s disease
∗ Corresponding author. Tel.: +1 207 244 9674; fax: +1 207 581 6128.
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[13,36] and may also be a risk factor for lowered cognitive per-
formance and cognitive decline in healthy individuals [1,43].
ApoE-4 carriers are also more vulnerable to cognitive deficits
related to risk factors such as low vitamin B12 blood concentra-
tions [3,4], peripheral vascular disease and atherosclerosis [15].
Yet, despite the evidence that both higher levels of tHcy and
the presence of the ApoE-4 allele are related to poorer cogni-
tive performance, few studies have tested the hypothesis that the
ApoE-4 genotype modifies relations between plasma tHcy and
cognitive performance [7,38].
In a community sample of persons 50–70 years old, the
association of higher tHcy with poorer performance on the
Rey Auditory Verbal Learning Test was stronger in persons
homozygous for the ApoE-4 allele as compared to all other
participants [38]. However, another community sample study of
persons 61–73 years old did not find that associations of tHcy
with cognitive decline were moderated by the ApoE-4 allele
[7].
0304-3940/$ – see front matter © 2007 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.neulet.2007.10.021
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Given the inconsistencies in the few studies available, we
tested the following hypotheses with respect to non-demented
community-based adults: (1) compared to persons without the
ApoE-4 allele, the magnitude of the association between tHcy
and cognitive performance is greater for ApoE-4 allele carriers;
(2) this modification of relations between tHcy and cognition by
ApoE genotype is not limited to global cognitive performance
but is evident for specific cognitive domains; and (3) this modi-
fication will be observed with adjustment for CVD events, CVD
risk factors, and blood concentrations of B-vitamins (folate,
vitamin B6, and vitamin B12).
The University of Maine approved this investigation.
Informed consent for data collection was obtained from all
participants in this community-based sample from the Maine-
Syracuse Longitudinal Study (MSLS), which began in 1975.
Recruitment and data collection procedures for the MSLS have
been described in detail [11]. This study is a cross-sectional
analysis of data obtained at the sixth wave of MSLS testing
(2001–2006), the first and only wave for which tHcy and ApoE
data were obtained. Of the 965 participants, aged between 26 and
98 years, subjects were excluded in the following sequence: (1)
no-ApoE genotype data obtained (n = 6); (2) dementia (n = 9);
(3) stroke (n = 32), (4) active dialysis treatment (n = 5); (5)
treatment for alcoholism (n = 1); (6) inability to read test mate-
rial (n = 1). Stroke, defined as a focal neurological deficit of
acute onset persisting more than 24 h, was based on self-
report and record review (with permission), but confirmed by
hospitalization, treatment, or both. The clinical diagnosis of
dementia was determined from cognitive data, self-report, and
medical records, using the National Institute of Neurological
and Communicative Diseases and Stroke/Alzheimer’s Disease
and Related Disorders Association (NINCDS-ADRDA) crite-
ria [27]. The characteristics of the final sample (n = 911) are
presented in Table 1.
Participants completed the Center for Epidemiological Stud-
ies Depression Scale (CES-D [34]) within one week prior to
neuropsychological testing. Following a fast from midnight,
a blood sample was drawn and a light breakfast was served.
A physical examination and neuropsychological testing fol-
lowed.
Fasting blood samples were collected in standard ethylene-
diaminetetraacetic acid tubes for plasma tHcy and plasma B6
determinations and in serum separator (gel and clot activator)
tubes for serum determinations. Plasma tHcy concentrations
were assessed using a fluorescence polarization immunoassay,
which has a coefficient of variation for tHcy assays of less than
3.5% [41]. Determination of plasma vitamin B6, high sensitivity
C-reactive protein (hs-CRP), serum folate, serum vitamin B12,
total cholesterol, triglycerides, glucose, and creatinine was per-
formed as recently described [11]. Standard ApoE genotyping
used polymerase chain reaction (PCR) and restriction enzyme
digest with HhaI [11,17].
We employed the Mini Mental State Examination (MMSE)
and the Maine-Syracuse neuropsychological test battery [11],
which included the Similarities test from the Wechsler Adult
Intelligence Scale (WAIS) and four composite scores resulting
from a previous factor analysis which identified four relatively
independent cognitive domains: Visual-Spatial Memory and
Organization, Scanning and Tracking, Verbal Episodic Memory
and Working Memory. Each composite score was constructed
by summing standard scores for multiple individual tests taken
from the Halstead Reitan Neuropsychological Test Battery, the
Wechsler Memory Scale-R, the original WAIS, and the WAIS III
[23].
Test scores were transformed to z-scores. This linear
transformation results in a mean of zero and a S.D. of 1.00
for each test and enables expression of regression coefficients
for the cognitive measures in terms of S.D. units. Factor
analytic methods and tests making up the composites are fully
described in a recent paper [11] and in the online supplement
(http://www.sciencedirect.com/science/journal/03043940).
These previously identified composites were confirmed via
replication of the factor analysis. Similarities (abstract reason-
ing) scores loaded on multiple factors and were treated as a
separate measure. In addition to composite scores based on
factor analysis, a Global Composite score was calculated by
averaging the z-scores for all individual tests (excluding the
MMSE). The Global Composite and MMSE were considered
separate measures of global performance.
A natural log transformation of the raw plasma tHcy values
(ln-tHcy) was necessary in order to achieve a normal distribution.
ApoE genotype was categorized as one or two 4 alleles (ApoE-
4 cohort) versus no 4 alleles (no-ApoE-4 cohort) given the
small number with two 4 alleles (n = 30).
Covariates were organized into three sets. The Basic set
included age (years), gender, education (years), number of
exposures to neuropsychological tests prior to wave six, and
race/ethnicity (non-Hispanic Caucasian or other). The CVD
set included CVD event/s (yes/no), diabetes mellitus (yes/no),
systolic blood pressure (mmHg, BP), presence of mild renal dys-
function (yes/no), total cholesterol (mg/dl), body mass index
(kg/m2, BMI), depressed mood (yes/no), hs-CRP, and self-
reported number of cigarettes smoked (per week), alcohol
consumption (cl/week), and coffee consumption (number of
24 cl cups/day). Diabetes mellitus was defined as follows: treat-
ment with insulin, oral antidiabetic agents, or fasting glucose
level of 126 mg/dl or above. Mild renal dysfunction was defined
as an estimated creatinine clearance using the Cockcroft–Gault
formula [6] of less than 60 ml/min [22]. Using the Framingham
Study criteria [9], the CVD event variable was defined by the
presence of any of the following: myocardial infarction (3.9%),
coronary artery disease (7.7%), congestive heart failure (2.3%),
angina pectoris (5.3%), or transient ischemic attack (3.7%). The
B-vitamin set included blood concentrations of folate, vitamin
B6 and vitamin B12. All of the covariates were related signifi-
cantly to the independent variables, the dependent variables, or
both.
The relation between ln-tHcy and the measures of cog-
nitive functioning was adjusted in a hierarchical progression
of regression models using the sets of covariates as follows:
(1) Unadjusted (no covariates); (2) the Basic set; (3) the
Basic + CVD set; and (4) the Expanded set (Basic + CVD + B-
vitamins). All variables within each model were entered
simultaneously.
Author's personal copy
66 M.F. Elias et al. / Neuroscience Letters 430 (2008) 64–69
Table 1
Demographic and health characteristics of the no-ApoE-4 allele and the ApoE-4 allele cohorts
Variable No-ApoE-4 allele (n = 667) ApoE-4 allele (n = 244)
Mean S.D. % Mean S.D. %
Homocysteine (mol/l) 10.0 3.6 9.8 3.2
Age (years) 62.6 12.9 60.7 12.3
Education (years) 14.6 2.7 14.6 2.8
Folate (ng/dl) 17.3 5.2 16.8 5.2
Vitamin B6 (PLPa), nmol/l 95.6 92.2 87.9 86.5
Vitamin B12 (pg/ml) 533.7 288.1 511.0 258.6
C-reactive protein 4.4 4.8 3.3 3.6
Systolic BP (mmHg) 132.3 21.3 129.6 22.2
Diastolic BP (mmHg) 71.1 10.1 69.9 9.7
Alcohol (cl/week) 4.5 7.8 4.8 10.1
Cigarettes (week) 8.2 34.5 12.8 43.2
Total cholesterol (mg/dl) 202.3 40.0 201.6 39.3
Body mass index (kg/m2) 29.5 5.9 29.4 6.4
Coffee (cups/day) 1.8 1.9 1.8 1.9
Gender (female) 58.5 60.7
Ethnicity (caucasian) 91.6 87.3
Diabetes mellitus 12.4 13.9
Obesity (BMI ≥ 29.9 kg/m2) 40.5 41.0
CVD event 15.1 14.8
Mild renal dysfunction 17.1 16.0
Depressed moodb 10.2 10.7
Folate deficitc 0.0 0.0
Vitamin B6 deficitd 14.6 14.8
Vitamin B12 deficite 3.5 4.1
Quintile 5 homocysteinef 19.8 20.1
a Pyridoxal 5′-phosphate.
b CES-depression scores >16.
c Folate deficiency defined as value <3 ng/ml.
d Vitamin B6 deficiency defined as value <30 nmol/l.
e Vitamin B12 deficiency defined as value <200 pg/ml.
f Homocysteine values ≥11.8mol/l.
Residual plots and absence of significant quadratic trends
(ps > .20) confirmed the appropriateness of the straight-line fit
for tHcy. For each model, tests of interactions of the independent
variables with age and gender were statistically non-significant
(ps > .10).
The number of persons classified into the possible ApoE
genotypes was as follows: 2/2 (n = 17), 2/3 (n = 103), 2/4
(n = 21), 3/3 (n = 547), 3/4 (n = 193), and 4/4 (n = 30). The ApoE-
4 cohort (2/4, 3/4, 4/4) represented 26.6% of our sample. This
representation is within the range (24–30%) reported in other
studies of ApoE [3,15,38].
The ApoE-4 cohort was younger (t = 2.00, p < .05), had
lower hs-CRP values (t = 3.51, p < .001) than the no-ApoE-4
cohort and had a modestly higher proportion (χ2 = 3.84, p < .05)
of minority persons (Table 1). No differences between ApoE
cohorts were observed for mean tHcy or B-vitamin concentra-
tions, low vitamin or high tHcy status, or other demographic or
health variables (p range = .09–.95).
With main effects in the model, statistically significant ApoE
by tHcy interactions (p < .05) were observed for the Unadjusted
model and for one or more adjusted models for the Global com-
posite, the MMSE, Working Memory, and Similarities. Thus in
a second step with respect to evaluating effect modification of
tHcy by ApoE, t-tests of the differences between regression coef-
ficients obtained for the two ApoE-4 cohorts were performed
for these variables. Table 2 shows the regression coefficients for
each ApoE group for the Global composite, the MMSE, Working
Memory, and Similarities. It may be seen that regression coef-
ficients were consistently higher for the ApoE-4 cohort than
for the no-ApoE-4 cohort. Significant differences (Table 2)
between regression coefficients were obtained for each of the
four variables. However, for the Global composite and Simi-
larities, differences between the regression coefficients did not
achieve statistical significance with adjustment for the Basic and
the Basic + CVD covariate sets, respectively.
For the Unadjusted model, statistically significant inverse
associations between tHcy and each cognitive score were
obtained within the no-ApoE-4 and the ApoE-4 cohort. For
the Basic model, all regression coefficients remained statisti-
cally significant for the ApoE-4 cohort, but only the regression
coefficient for the Global composite remained significant for
the no-ApoE-4 cohort. When the CVD covariate set was intro-
duced, and with further addition of the B-vitamin set, none
of the regression coefficients for the no-ApoE-4 cohort were
significant. For these models regression coefficients within the
ApoE-4 cohort remained significant for the Global composite,
MMSE, and Working Memory but were non-significant for Sim-
ilarities. It should be noted that with adjustment for the Basic
Author's personal copy
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Table 2
Regression coefficients (β), standard errors (S.E.) and significance levels (p<) for t-tests of the differences between regression coefficients for the No-Apoe-4 and
Apoe-4 groups relating natural log plasma homocysteine to the cognitive measuresa
Cognitive outcome Unadjusted model Basic model Basic + CVD model Expanded model
No-Apoe-
4
Apoe-4 p< No-Apoe-
4
Apoe-4 p< No-Apoe-
4
Apoe-4 p< No-Apoe-
4
Apoe-4 p<
Global
β −.807*** −1.120*** .05 −.213* −.412* NS −.029 −.491** .001 .054 −.460* .001
S.E. .123 .216 .106 .177 .110 .186 .118 .196
MMSE
β −.471*** −.805*** .05 −.183 −.602** .01 −.041 −.658** .001 .060 −.562* .001
S.E. .124 .235 .127 .219 .129 .234 .139 .250
Similarities
β −.379** −.852*** .01 −.202 −.493* .05 −.087 −.377 NS .045 −.288 .05
S.E. .126 .223 .121 .206 .128 .222 .137 .234
Working memory
β −.376** −.922*** .001 −.103 −.568* .01 .019 −.712** .001 .013 −.663** .001
S.E. .127 .217 .129 .223 .137 .233 .148 .248
NS, non-significant.
a Values for t-tests of differences between βs are shown in the online supplement (Table S2, http://www.sciencedirect.com/science/journal/03043940).
* p < .05.
** p < .01.
*** p < .001.
covariate set, Similarities scores were significantly (p < .05) cor-
related with five of the eleven CVD covariates (BMI, CVD
events, diabetes, systolic BP, and alcohol use; r range = +.11 to
−.20), while the other cognitive variables were correlated with
no more than three CVD variables (r range = +.14 to −.23).
Statistically significant main effects for the Unadjusted and
Basic models were observed for the Visual Spatial Memory
and Organization (β = −0.785, p < .001; β = −0.277, p < .01)
and Scanning and Tracking (β = −1.011, p < .001; β = −0.300,
p < .01) composites. The Scanning and Tracking main effect per-
sisted with adjustment for the CVD covariate set (β = −0.209,
p < .05), but was attenuated when B-vitamins were added to the
model (β = −0.174, p > .05). A main effect observed for the
Verbal Episodic Memory composite in the Unadjusted model
(β = −0.494, p < .001) did not persist with adjustment for the
Basic covariate set (β = 0.078, p > .20).
In a final analysis, two CVD sub-models were formed from
the CVD covariate set. The first sub-model included the follow-
ing “primary” CVD variables: CVD events, diabetes mellitus,
systolic BP, mild renal dysfunction, total cholesterol, BMI, and
hs-CRP. The second, a “life style set”, included depressed mood
and cigarette, alcohol, and coffee consumption. Findings for
both sub-models were the same as those reported above for the
CVD model.
To illustrate the magnitude of statistical effects, we com-
pared persons with tHcy values in the highest quintile (Q5,
tHcy > 11.8mol/l) versus the lower four quintiles (Q1–Q4)
with regard to two overall measures of cognitive performance,
the MMSE and the Global composite, with adjustment for
the expanded covariate set. Within the ApoE-4 cohort, per-
sons in tHcy Q5 performed close to 0.30S.D. units below
persons in the lower tHcy quintiles on the Global compos-
ite (β = −0.294, p < .04). This difference between persons in
tHcy Q5 and persons in Q1–Q4 was at 0.40S.D. for the MMSE
(β = −0.402, p < .01). However, within the no-ApoE-4 cohort,
persons in tHcy Q5 did not differ in performance from persons
in Q1–Q4 on either the Global composite (β = −0.016, p > .50)
or the MMSE (β = −0.008, p > .50). Differences between these
regression coefficients for the ApoE cohorts (β = −0.294 versus
−0.016 and β = −0.402 versus −0.008, respectively) were sta-
tistically significant for both the Global composite and MMSE
(ps < .01).
The magnitude of inverse association between tHcy and cog-
nition was consistently higher for the ApoE-4 cohort than
for the no-ApoE-4 cohort for all covariate models. Results
within each ApoE cohort varied somewhat depending upon the
model employed. For instance, with no adjustment for covari-
ates, significant inverse associations for all cognitive variables
were observed for both ApoE cohorts. With adjustment for the
basic covariate set, primarily demographic characteristics, only
the significant result for the Global composite remained for the
no-ApoE-4 cohort. However, results persisted for the ApoE-
4 cohort for the Global Composite, MMSE, Similarities, and
Working Memory.
With further adjustment for the CVD and the B-vitamin
covariate sets, the inverse relation between tHcy and Global cog-
nitive performance for the no-ApoE-4 cohort was markedly
attenuated and non-significant. In contrast, for the ApoE-4
cohort, further adjustment for the CVD and the expanded covari-
ate set resulted in only modest attenuation of inverse relations
between tHcy and cognitive performance for the Global com-
posite, MMSE, and Working Memory. Associations between
Similarities (abstract reasoning) scores and tHcy did not persist
with adjustment for the CVD covariate set. The greater attenua-
tion of the association between tHcy and Similarities scores, as
compared to Global composite, MMSE, and Working Memory
Author's personal copy
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scores, may reflect the fact that Similarities was correlated sig-
nificantly with a greater number of the CVD variables than were
the other cognitive scores.
Although the interaction between ApoE genotype and tHcy
has been studied at the cellular level to explain their effect on
atheroma formation [21,47] and neuronal cell cycle dysregula-
tion in the brain [29], only two studies report the modification of
tHcy relations with cognitive performance by the ApoE geno-
type. Dufouil et al. [7] did not find that ApoE genotype modified
associations of tHcy with cognitive decline. Schafer et al. [38]
found that the cross-sectional association of tHcy with perfor-
mance on the Rey Auditory Verbal Learning Test was stronger
in individuals homozygous for the ApoE-4 allele than those
carrying only one 4 allele or no 4 alleles. Our study differed
from this study in that we employed fasting tHcy values, adjusted
for vitamin concentrations as well as CVD factors and combined
cohorts carrying either one or two ApoE-4 alleles for our major
analyses given statistical power considerations.
Because of the evidence that higher tHcy might be neurotoxic
[14,20,24,32], it is instructive to consider potential mechanisms
involved in the relation between the ApoE-4 allele and cog-
nitive performance, particularly those mechanisms pertaining
to neuronal damage and repair. It has been argued that atro-
phy of the hippocampus and loss of its connectivity play a role
in ApoE-4-related deficits in test performance depending on
memory [43]. Also, there is evidence that cholinergic transmit-
ter decrements in those persons with an ApoE-4 genotype are
seen in temporo-parietal brain areas involving integrative, psy-
chomotor and visual abilities [31]. Small et al. [42] argue that
the interplay between several mechanisms may better explain
the broad range of deficits seen in ApoE-4 carriers. ApoE-4
is related to cardiovascular disease [16,42,44] which, in turn, is
related to cognitive deficit [10]. ApoE-4 genotype has also been
implicated in the altered metabolism of beta-amyloid and the
formation of neurofibrillary tangles [44]. Additionally, ApoE-
4 genotype is related to impairments in neuronal maintenance
and repair [18]. Though speculative, the interplay between tHcy
and ApoE-4 genotype may be more than a summation of differ-
ent deleterious effects, i.e. ApoE-4 genotype is associated with
neuronal susceptibility to insult while higher tHcy is associated
with greater neuronal death.
Limitations of this study include: (1) the cross-sectional
design; and (2) the relatively high levels of education of our
participants which may serve to attenuate the magnitude of asso-
ciations between tHcy and cognitive performance for both ApoE
cohorts.
In an era focused on pre-clinical disease and prevention,
the magnitude of the impact of plasma tHcy and ApoE geno-
type on cognitive performance is crucial. With adjustment for
the Expanded model (Basic + CVD + B-vitamin covariates), we
found that persons with high, as versus low, plasma tHcy in the
presence of an ApoE-4 allele performed 0.30S.D. and 0.40S.D.
lower on the Global composite and the MMSE, respectively.
Deficits of this magnitude are of considerable importance at the
population level and constitute a risk factor for dementia [8].
Our results are consistent with a model in which the ApoE-
4 allele is seen as conferring vulnerability to other risk factors
and pathophysiological phenomena related to lower cognitive
performance [4]. Additional studies are needed in order to under-
stand the mechanism explaining the interplay between plasma
tHcy and ApoE genotype with regard to cognitive performance
in a non-demented sample.
Acknowledgments
This study was supported by Research Grant HL67358 from
the National Heart, Lung, and Blood Institute, National Institutes
of Health (USA), Research Grant AG03055 from the National
Institute on Aging, National Institutes of Health (USA), the
Alzheimer’s Research Trust (UK), and the Charles Wolfson
Charitable Trust (UK).
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.neulet.2007.10.021.
References
[1] P. Bretsky, J.M. Guralnik, L. Launer, M. Albert, T.E. Seeman, The role
of APOE-epsilon4 in longitudinal cognitive decline: MacArthur studies of
successful aging, Neurology 60 (2003) 1077–1081.
[2] M.M. Budge, C. de Jager, E. Hogervorst, A.D. Smith, Total plasma homo-
cysteine, age, systolic blood pressure, and cognitive performance in older
people, J. Am. Geriatr. Soc. 50 (2002) 2014–2018.
[3] D. Bunce, M. Kivipelto, A. Wahlin, E. Apolipoprotein, B vitamins, and
cognitive function in older adults, J. Gerontol. B Psychol. Sci. Soc. Sci. 60
(2005) P41–P48.
[4] D. Bunce, M. Kivipelto, A. Wahlin, Utilization of cognitive support in
episodic free recall as a function of apolipoprotein E and vitamin B12 or
folate among adults aged 75 years and older, Neuropsychology 18 (2004)
362–370.
[5] R. Clarke, A.D. Smith, K.A. Jobst, H. Refsum, L. Sutton, P.M. Ueland,
Folate, vitamin B12, and serum total homocysteine levels in confirmed
Alzheimer disease, Arch. Neurol. 55 (1998) 1449–1455.
[6] D.W. Cockcroft, M.H. Gault, Prediction of creatinine clearance from serum
creatinine, Nephron 16 (1976) 31–41.
[7] C. Dufouil, A. Alperovitch, V. Ducros, C. Tzourio, Homocysteine, white
matter hyperintensities, and cognition in healthy elderly people, Ann. Neu-
rol. 53 (2003) 214–221.
[8] M.F. Elias, A. Beiser, P.A. Wolf, R. Au, R.F. White, R.B. D’Agostino, The
preclinical phase of Alzheimer disease: a 22-year prospective study of the
Framingham Cohort, Arch. Neurol. 57 (2000) 808–813.
[9] P.K. Elias, M.F. Elias, R.B. D’Agostino, L.M. Sullivan, P.A. Wolf, Serum
cholesterol and cognitive performance in the Framingham Heart Study,
Psychosom. Med. 67 (2005) 24–30.
[10] M.F. Elias, P.K. Elias, M.A. Robbins, P.A. Wolf, R.B. D’Agostino, Car-
diovascular risk factors and cognitive functioning: an epidemiological
perspective, in: S. Waldstein, M.F. Elias (Eds.), Neuropsychology of Car-
diovascular Disease, Lawrence Erlbaum Associates, Inc., Hillsdale, NJ,
2001, pp. 83–105.
[11] M.F. Elias, M.A. Robbins, M.M. Budge, P.K. Elias, S.L. Brennan, C. John-
ston, Z. Nagy, C.J. Bates, Homocysteine, folate, and vitamins B6 and
B12 blood levels in relation to cognitive performance: the Maine-Syracuse
study, Psychosom. Med. 68 (2006) 547–554.
[12] M.F. Elias, L.M. Sullivan, R.B. D’Agostino, P.K. Elias, P.F. Jacques, J. Sel-
hub, S. Seshadri, R. Au, A. Beiser, P.A. Wolf, Homocysteine and cognitive
performance in the Framingham offspring study: age is important, Am. J.
Epidemiol. 162 (2005) 644–653.
[13] L.A. Farrer, L.A. Cupples, J.L. Haines, B. Hyman, W.A. Kukull, R.
Mayeux, R.H. Myers, M.A. Pericak-Vance, N. Risch, C.M. van Duijn,
Author's personal copy
M.F. Elias et al. / Neuroscience Letters 430 (2008) 64–69 69
Effects of age, sex, and ethnicity on the association between apolipopro-
tein E genotype and Alzheimer disease. A meta-analysis. APOE and
Alzheimer Disease Meta Analysis Consortium, J. Am. Med. Assoc. 278
(1997) 1349–1356.
[14] E.M. Fykse, E.G. Iversen, F. Fonnum, Inhibition of l-glutamate uptake into
synaptic vesicles, Neurosci. Lett. 135 (1992) 125–128.
[15] M.N. Haan, L. Shemanski, W.J. Jagust, T.A. Manolio, L. Kuller, The role
of APOE epsilon4 in modulating effects of other risk factors for cog-
nitive decline in elderly persons, J. Am. Med. Assoc. 282 (1999) 40–
46.
[16] G.J. Hankey, J.W. Eikelboom, Homocysteine and vascular disease, Lancet
354 (1999) 407–413.
[17] J.E. Hixson, D.T. Vernier, Restriction isotyping of human apolipoprotein
E by gene amplification and cleavage with HhaI, J. Lipid. Res. 31 (1990)
545–548.
[18] K. Horsburgh, M.O. McCarron, F. White, J.A. Nicoll, The role of
apolipoprotein E in Alzheimer’s disease, acute brain injury and cerebrovas-
cular disease: evidence of common mechanisms and utility of animal
models, Neurobiol. Aging 21 (2000) 245–255.
[19] D.M. Kado, A.S. Karlamangla, M.H. Huang, A. Troen, J.W. Rowe, J. Sel-
hub, T.E. Seeman, Homocysteine versus the vitamins folate, B6, and B12
as predictors of cognitive function and decline in older high-functioning
adults: MacArthur studies of successful aging, Am. J. Med. 118 (2005)
161–167.
[20] Kruman II, C. Culmsee, S.L. Chan, Y. Kruman, Z. Guo, L. Penix, M.P.
Mattson, Homocysteine elicits a DNA damage response in neurons that
promotes apoptosis and hypersensitivity to excitotoxicity, J. Neurosci. 20
(2000) 6920–6926.
[21] S.R. Lentz, Mechanisms of homocysteine-induced atherothrombosis, J.
Thromb. Haemost. 3 (2005) 1646–1654.
[22] G. Leoncini, F. Viazzi, D. Parodi, S. Vettoretti, E. Ratto, M. Ravera, C.
Tomolillo, M. Del Sette, G.P. Bezante, G. Deferrari, R. Pontremoli, Mild
renal dysfunction and subclinical cardiovascular damage in primary hyper-
tension, Hypertension 42 (2003) 14–18.
[23] M.D. Lezak, D.B. Howieson, D.W. Loring, Neuropsychological Assess-
ment, Oxford University Press, New York, 2004, xiv, 1016 pp.
[24] S.A. Lipton, W.K. Kim, Y.B. Choi, S. Kumar, D.M. D’Emilia, P.V. Rayudu,
D.R. Arnelle, J.S. Stamler, Neurotoxicity associated with dual actions of
homocysteine at the N-methyl-D-aspartate receptor, Proc. Natl. Acad. Sci.
U.S.A. 94 (1997) 5923–5928.
[25] A. McCaddon, G. Davies, P. Hudson, S. Tandy, H. Cattell, Total serum
homocysteine in senile dementia of Alzheimer type, Int. J. Geriatr. Psychi-
atry 13 (1998) 235–239.
[26] A. McCaddon, P. Hudson, G. Davies, A. Hughes, J.H. Williams, C. Wilkin-
son, Homocysteine and cognitive decline in healthy elderly, Dement.
Geriatr. Cogn. Disord 12 (2001) 309–313.
[27] G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, E.M.
Stadlan, Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-
ADRDA Work Group under the auspices of Department of Health and
Human Services Task Force on Alzheimer’s Disease, Neurology 34 (1984)
939–944.
[28] J.W. Miller, R. Green, M.I. Ramos, L.H. Allen, D.M. Mungas, W.J. Jagust,
M.N. Haan, Homocysteine and cognitive function in the Sacramento Area
Latino Study on aging, Am. J. Clin. Nutr. 78 (2003) 441–447.
[29] Z. Nagy, Cell cycle-related protein expression in Alzheimer’s disease and
vascular disease, Int. Psychogeriatr. 15 (Suppl. 1) (2003) 77–79.
[30] B.P. Nathan, S. Bellosta, D.A. Sanan, K.H. Weisgraber, R.W. Mahley, R.E.
Pitas, Differential effects of apolipoproteins E3 and E4 on neuronal growth
in vitro, Science 264 (1994) 850–852.
[31] R. Parasuraman, P.M. Greenwood, T. Sunderland, The apolipoprotein E
gene, attention, and brain function, Neuropsychology 16 (2002) 254–274.
[32] R.B. Parsons, R.H. Waring, D.B. Ramsden, A.C. Williams, In vitro effect
of the cysteine metabolites homocysteic acid, homocysteine and cysteic
acid upon human neuronal cell lines, Neurotoxicology 19 (1998) 599–603.
[33] N.D. Prins, T. Den Heijer, A. Hofman, P.J. Koudstaal, J. Jolles, R. Clarke,
M.M. Breteler, Homocysteine and cognitive function in the elderly: the
Rotterdam Scan Study, Neurology 59 (2002) 1375–1380.
[34] L.S. Radloff, The CES-D scale: a self-report depression scale for research
in the general population, Appl. Psychol. Meas. 1 (1977) 385–401.
[35] H. Refsum, P.M. Ueland, O. Nygard, S.E. Vollset, Homocysteine and car-
diovascular disease, Annu. Rev. Med. 49 (1998) 31–62.
[36] B. Regland, K. Blennow, T. Germgard, A.C. Koch-Schmidt, C.G. Gottfries,
The role of the polymorphic genes apolipoprotein E and methylene-
tetrahydrofolate reductase in the development of dementia of the Alzheimer
type, Dement. Geriatr. Cogn. Disord 10 (1999) 245–251.
[37] K.M. Riggs, A. Spiro 3rd, K. Tucker, D. Rush, Relations of vitamin B-
12, vitamin B-6, folate, and homocysteine to cognitive performance in the
Normative Aging Study, Am. J. Clin. Nutr. 63 (1996) 306–314.
[38] J.H. Schafer, T.A. Glass, K.I. Bolla, M. Mintz, A.E. Jedlicka, B.S. Schwartz,
Homocysteine and cognitive function in a population-based study of older
adults, J. Am. Geriatr. Soc. 53 (2005) 381–388.
[39] J. Selhub, L.C. Bagley, J. Miller, I.H. Rosenberg, B vitamins, homocysteine,
and neurocognitive function in the elderly, Am. J. Clin. Nutr. 71 (2000)
614S–620S.
[40] S. Seshadri, A. Beiser, J. Selhub, P.F. Jacques, I.H. Rosenberg, R.B.
D’Agostino, P.W. Wilson, P.A. Wolf, Plasma homocysteine as a risk fac-
tor for dementia and Alzheimer’s disease, N. Engl. J. Med. 346 (2002)
476–483.
[41] M.T. Shipchandler, E.G. Moore, Rapid, fully automated measurement of
plasma homocyst(e)ine with the Abbott IMx analyzer, Clin. Chem. 41
(1995) 991–994.
[42] B.J. Small, A.B. Graves, C.L. McEvoy, F.C. Crawford, M. Mullan, J.A.
Mortimer, Is APOE-epsilon4 a risk factor for cognitive impairment in
normal aging? Neurology 54 (2000) 2082–2088.
[43] B.J. Small, C.B. Rosnick, L. Fratiglioni, L. Backman, Apolipoprotein E
and cognitive performance: a meta-analysis, Psychol. Aging 19 (2004)
592–600.
[44] J.D. Smith, Apolipoproteins and aging: emerging mechanisms, Ageing Res.
Rev. 1 (2002) 345–365.
[45] C.E. Teunissen, A.H. Blom, M.P. Van Boxtel, H. Bosma, C. de Bruijn,
J. Jolles, B.A. Wauters, H.W. Steinbusch, J. de Vente, Homocysteine: a
marker for cognitive performance? A longitudinal follow-up study, J. Nutr.
Health Aging 7 (2003) 153–159.
[46] K.L. Tucker, N. Qiao, T. Scott, I. Rosenberg, A. Spiro 3rd, High homo-
cysteine and low B vitamins predict cognitive decline in aging men: the
Veterans Affairs Normative Aging Study, Am. J. Clin. Nutr. 82 (2005)
627–635.
[47] J. Zhou, G.H. Werstuck, S. Lhotak, A.B. de Koning, S.K. Sood, G.S. Hos-
sain, J. Moller, M. Ritskes-Hoitinga, E. Falk, S. Dayal, S.R. Lentz, R.C.
Austin, Association of multiple cellular stress pathways with accelerated
atherosclerosis in hyperhomocysteinemic apolipoprotein E-deficient mice,
Circulation 110 (2004) 207–213.
